Melfalan Sun

Melphalan, the active ingredient in Melfalan Sun, is an alkylating agent (nitrogen mustard) presented as an intravenous formulation for use in oncology patients. It is employed in the treatment of certain hematologic malignancies and solid tumors, acting by interfering with DNA replication and transcription to induce cancer cell death.

GNH USA supplies Melfalan Sun as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for importers.

Melfalan Sun (melphalan) is used in chemotherapy regimens targeting malignant cells in several cancer types.

- Multiple myeloma: reduces malignant plasma cell burden and prolongs survival. - Ovarian cancer: contributes to tumor shrinkage when combined with other agents. - Melanoma: provides cytotoxic activity against metastatic lesions. - Other solid tumors: offers therapeutic benefit as part of combination protocols for various solid malignancies.

Melfalan Sun may cause a range of adverse reactions, which are classified by frequency and severity.

Common Side Effects: - Nausea and vomiting: gastrointestinal upset commonly reported during treatment. - Myelosuppression: decreased white blood cells, red cells, and platelets. - Fatigue: generalized tiredness affecting daily activities. - Alopecia: temporary hair loss on scalp and body.

Serious or Rare Side Effects: - Secondary malignancies: risk of therapy‑related leukemia or other cancers. - Severe infection: due to profound neutropenia and immunosuppression. - Pulmonary toxicity: interstitial pneumonitis or fibrosis in rare cases.

Before initiating Melfalan Sun, clinicians should evaluate several safety considerations to minimize risks.

- Baseline blood counts: obtain complete blood count and differential to assess marrow reserve. - Renal function: evaluate creatinine clearance as melphalan is renally excreted. - Hepatic status: monitor liver enzymes in patients with hepatic impairment. - Concomitant myelosuppressive therapy: adjust dosing or schedule when combined with other cytotoxics. - Pregnancy and lactation: avoid use unless benefits outweigh potential fetal risk. - Store at ambient temperature: keep vials in original packaging, protect from light and moisture, and do not freeze.

Melphalan can interact with other medicines, altering its efficacy or toxicity profile.

Major Interactions (Avoid): - Live vaccines: administration of live attenuated vaccines during melphalan therapy may lead to uncontrolled infection because of drug‑induced immunosuppression. - Strong CYP inducers: drugs such as rifampin or carbamazepine can increase melphalan metabolism, potentially lowering its anticancer activity.

Moderate Interactions (Monitor Closely): - Anticoagulants: melphalan‑induced thrombocytopenia can enhance the anticoagulant effect, requiring closer INR monitoring. - Nephrotoxic drugs: concurrent use of agents like cisplatin or aminoglycosides may worsen renal function and affect melphalan clearance. - Other alkylating agents: combined use with cyclophosphamide or ifosfamide can produce additive bone‑marrow suppression, necessitating dose modifications.